Pharmaceuticals News and Research

RSS

First Edition: November 30, 2012

Today's headlines include news about the continuing partisan back and forth regarding "fiscal cliff" negotiations as well as reports on the health law's implementation.

30 Nov 2012

VAC-3S immunotherapeutic vaccine for HIV completes first clinical development phase

InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, has just announced successful completion of the first clinical development phase for VAC-3S immunotherapy in the treatment of HIV infections.

30 Nov 2012

Seven U of M faculty named American Association for the Advancement of Science Fellows

Seven faculty at the University of Minnesota have been named a Fellow of the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers, and recognizes scientifically or socially distinguished efforts to advance science or its applications.

30 Nov 2012

Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

Boehringer Ingelheim today announced that new data evaluating volasertib, an investigational polo-like kinase (Plk) inhibitor, will be presented at the 54th American Society of Hematology (ASH) annual meeting taking place December 8-11 in Atlanta, Ga.

30 Nov 2012

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

DARA BioSciences, Inc., a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today it has submitted an Orphan Drug Application to the U.S. Food and Drug Administration (FDA) for KRN5500, a compound in development to treat a painful form of chronic chemotherapy-induced peripheral neuropathy (CCIPN).

30 Nov 2012

U.K. NICE issues final draft guidance on Alimera Sciences’ ILUVIEN

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance indicating that ILUVIEN is not recommended for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

30 Nov 2012

Pivotal Therapeutics reports loss of $811,164 for third quarter 2012

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on cardiovascular disease and overall health today announced its financial results and operational highlights for the quarter ended September 30, 2012. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.

30 Nov 2012

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced the presentation of data evaluating the preclinical safety and efficacy of two of the Company's novel, potent and selective small molecule inhibitors. These inhibitors individually target DOT1L and EZH2, members of a class of epigenic enzymes called histone methyltransferases (HMTs).

30 Nov 2012

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).

29 Nov 2012

ArmaGen closes $17M Series A financing

ArmaGen Technologies, Inc. today announced the closing of a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics.

29 Nov 2012

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

InSite Vision Incorporated today announced that patient enrollment has been completed in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

29 Nov 2012

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.

29 Nov 2012

Bend Research, PATH and FhCMB develop new technology for thermostable vaccine production

Bend Research Inc., PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announce the development of a new technology for the production of thermostable vaccines. Utilizing novel formulation and spray-drying processing methods, the technology has enabled scientists at Bend Research, PATH, and FhCMB to develop a spray-dried influenza vaccine product that is stable at 50°C for over 2 months. The technology can also be applied to emerging influenza and other vaccines.

29 Nov 2012

Fertility treatment auto-injector: an interview with Lai Chiu Tang, Senior Industrial Designer at Cambridge Consultants

During IVF treatment you will need to take certain drugs. For example, for IVF it will be Follicle Stimulating Hormones (FSH) which are used to stimulate the ovaries to produce a mature egg so that they can be fertilised externally and then put back into the womb.

29 Nov 2012

Pharma companies improving access to medicines but lack oversight of outsourced clinical trials, analysis says

Pharmaceutical companies are showing "greater accountability in the boardroom today over access to medicines, with more openness, targets and investment in drugs relevant to the poor," but they "show no evidence that they adequately supervise the conduct of outsourced clinical drug trials, according to a new analysis released on Wednesday," the Financial Times reports.

29 Nov 2012

Pall first quarter 2013 sales decrease 3.6% to $627.6 million

Pall Corporation today reported financial results for the first quarter of fiscal year 2013 which ended on October 31, 2012.

From Pall Corporation 29 Nov 2012

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT® (lacosamide) C-V data at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4.

29 Nov 2012

CEL-SCI's Multikine cancer drug receives key Japanese patent

CEL-SCI Corporation today announced that the Japanese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine (Leukocyte Interleukin, Injection).

29 Nov 2012

Rexahn intends to offer shares of common stock and warrants

Rexahn Pharmaceuticals, Inc. today announced that it intends to offer shares of its common stock and warrants to purchase common stock in an underwritten public offering.

29 Nov 2012

Pfizer completes acquisition of NextWave Pharmaceuticals

Pfizer Inc. today announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc., a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

29 Nov 2012

Pharmaceuticals News and Research

First Edition: November 30, 2012

VAC-3S immunotherapeutic vaccine for HIV completes first clinical development phase

Seven U of M faculty named American Association for the Advancement of Science Fellows

Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

U.K. NICE issues final draft guidance on Alimera Sciences’ ILUVIEN

Pivotal Therapeutics reports loss of $811,164 for third quarter 2012

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

ArmaGen closes $17M Series A financing

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Bend Research, PATH and FhCMB develop new technology for thermostable vaccine production

Fertility treatment auto-injector: an interview with Lai Chiu Tang, Senior Industrial Designer at Cambridge Consultants

Pharma companies improving access to medicines but lack oversight of outsourced clinical trials, analysis says

Pall first quarter 2013 sales decrease 3.6% to $627.6 million

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

CEL-SCI's Multikine cancer drug receives key Japanese patent

Rexahn intends to offer shares of common stock and warrants

Pfizer completes acquisition of NextWave Pharmaceuticals

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence